» Articles » PMID: 26615031

Intestinal Pseudo-obstruction in Patients with Systemic Sclerosis: an Analysis of the Nationwide Inpatient Sample

Overview
Specialty Rheumatology
Date 2015 Nov 29
PMID 26615031
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Intestinal pseudo-obstruction is a rare gastrointestinal complication in patients with SSc without large studies examining its prevalence or outcomes. We aimed to compare outcomes in SSc patients with intestinal pseudo-obstruction to patients with intestinal pseudo-obstruction secondary to other causes, and SSc patients without intestinal pseudo-obstruction.

Methods: This is a case-control study using the Healthcare Cost and Utilization Project Nationwide Inpatient Sample for the period 2002-2011. We included patients with the previously validated International Classification of Diseases-Clinical Modification-9 code 710.1 for SSc in combination with codes for intestinal pseudo-obstruction, and determined length of hospitalization and the risks for surgical procedures, use of total parenteral nutrition (TPN) and in-hospital mortality.

Results: A total of 193 610 SSc hospitalizations occurred in the USA between 2002 and 2011, of which 5.4% (n = 10 386) were associated with a concurrent intestinal pseudo-obstruction diagnosis (cases). In-hospital mortality was 7.3%. In multivariate analyses, cases were more likely to die during the inpatient stay and to receive TPN than patients with idiopathic intestinal pseudo-obstruction (control group 1), patients with intestinal pseudo-obstruction and diabetes (control group 2), and SSc patients without intestinal pseudo-obstruction (control group 3). Cases had longer in-hospital stay than control groups 2 and 3, and were less likely to undergo surgical procedures than control groups 1 and 2.

Conclusion: Intestinal pseudo-obstruction is a rare cause of hospitalization in patients with SSc, but is associated with high in-hospital mortality in comparison with other SSc patients and those with intestinal pseudo-obstruction secondary to other causes.

Citing Articles

Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis Without Cutaneous Findings or Rapidly Progressive Lung Disease: A Case Report.

Ho F, Jain B, Pierre-Wright M, Wachsberg K J Gen Intern Med. 2024; 39(13):2595-2599.

PMID: 39285070 PMC: 11436552. DOI: 10.1007/s11606-024-08866-9.


Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin....

Matsuda K, Sugimoto E, Ako Y, Kitamura M, Miyahara M, Kotani H J Dermatol. 2024; 51(6):741-751.

PMID: 38558171 PMC: 11483899. DOI: 10.1111/1346-8138.17202.


Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration.

Matsuda K, Yoshizaki A, Kuzumi A, Toyama S, Awaji K, Miyake T Rheumatology (Oxford). 2023; 62(9):3139-3145.

PMID: 36825818 PMC: 10473276. DOI: 10.1093/rheumatology/kead093.


Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.

McMahan Z, Kulkarni S, Chen J, Chen J, Xavier R, Pasricha P Nat Rev Rheumatol. 2023; 19(3):166-181.

PMID: 36747090 DOI: 10.1038/s41584-022-00900-6.


Systemic sclerosis.

Volkmann E, Andreasson K, Smith V Lancet. 2022; 401(10373):304-318.

PMID: 36442487 PMC: 9892343. DOI: 10.1016/S0140-6736(22)01692-0.